Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.63 |
| ▸ | BRAF | P15056 | 12/20 | 0.57 |
| ▸ | RAF1 | P04049 | 7/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.57 |
| ▸ | CSF1R | P07333 | 2/20 | 0.52 |
| ▸ | PLK4 | O00444 | 2/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | LCK | P06239 | 2/20 | 0.52 |
| ▸ | FYN | P06241 | 2/20 | 0.52 |
| ▸ | LYN | P07948 | 2/20 | 0.52 |
| ▸ | RET | P07949 | 2/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.52 |
| ▸ | AXL | P30530 | 2/20 | 0.52 |
| ▸ | FRK | P42685 | 2/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6014190 | 0.88 | KDR (0.59) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL618015 | 0.88 | KDR (0.59) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL8738426 | 0.88 | KDR (0.59) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL12391452 | 0.88 | KDR (0.59) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL20739472 | 0.88 | KDR (0.59) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL12355381 | 0.88 | KDR (0.59) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL167964 | 0.87 | KDR (0.68) | KDRBRAFRAF1EPHX2CSF1R | |
| Hydrochloric Acid SCHEMBL621069 | 0.87 | KDR (0.58) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL13648151 | 0.85 | KDR (0.57) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL14422931 | 0.85 | RAF1 (0.60) | KDRBRAFRAF1EPHX2CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9381177-B2 | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-05 | — | — | US | disclosed |
| US-9381177-B2 | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-05 | — | — | US | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130261120-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| US-20130261120-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| EP-1636585-B2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHERCARE LLC (US) | 2012-06-07 | — | — | US | disclosed |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-01-31 | — | — | US | disclosed |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-01-31 | — | — | US | disclosed |
| EP-1636585-B1 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
| US-7235576-B1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235576-B1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| WO-2007053574-A2 | COMBINATIONS COMPRISING SORAFENIB AND INTERFERON FOR THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | FLT4, FLT1, FLT3 | KDR 44/4885BRAF 31/4885RAF1 51/4885 |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | MAPK1, MAPK8, MAPK3 | KDR 2141/4885BRAF 344/4885RAF1 452/4885 |
| US-20130261120-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | KIT, CHUK, IKBKB | KDR 904/4885BRAF 43/4885RAF1 532/4885 |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BRAF, RAF1, ARAF | KDR 958/4885BRAF 1/4885RAF1 2/4885 |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDR 456/4885BRAF 1/4885RAF1 2/4885 |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDR 567/4885BRAF 1/4885RAF1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.